Titlebook: Engineering Biomaterials for Neural Applications; Elizabeth Nance Book 2022 The Editor(s) (if applicable) and The Author(s), under exclusi

hypnotic

Scleroderma

Theranostic Nanomaterials for Brain Injuryunseen in the acute brain injury literature. Whatever approach is taken, the informed design of nanomaterials for acute brain injury must combine information from varied disciplines including, though not limited to, neurobiology and materials science. A brief introduction to the pathophysiologies of

航海太平洋

Configurable Models of the Neurovascular Unitrain homeostasis and proper neuronal function. The BBB is composed of multiple cell types arranged in a complex 3D structure that enables sophisticated interplay between endothelial cells, pericytes, glial cells, and neurons. This complex is known as the “neurovascular unit” (NVU). Several neuropath

群居动物

Nano-Based Probes for the Brain Extracellular Environmentain’s function is determined by complex interactions of cells within the brain parenchyma, the functional unit of brain tissue critical for supporting and protecting cells. In fact, trauma or disease to the brain parenchyma can result in a loss of cognitive function and, in severe cases, death (Bonk

扫兴

Engineered Materials for Probing and Perturbing Brain Chemistrynformation from the external world, and to initiate and send commands to effector cells in response to sensory cues to bring about physiological or behavioral change. The adult human brain is estimated to contain more than 80 × 10. neurons making trillions of synaptic connections (junctions between

悬崖

座右铭

Bioresponsive Nanomaterials for CNS Disease are few medicines available to diagnose and treat neurological disorders and progress on developing new medicines has been limited. One major challenge is the narrow therapeutic window of payloads that act in the CNS – significant transport barriers restrict bioavailability yet the CNS is sensitive

松鸡

季雨

令人悲伤

Theranostic Nanomaterials for Brain Injuryeir prevalence, the intricacies of the pathologies have limited the clinical impact of promising preclinical results with small-molecule, yielding little in terms of pharmacologic interventions for acute, subacute, and chronic disease processes. Controlling the physicochemical properties of a nanoma